These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 20024740)

  • 1. Which method of adherence measurement is most suitable for daily use to predict virological failure among immigrant and non-immigrant HIV-1 infected patients?
    Nellen JF; Nieuwkerk PT; Burger DM; Wibaut M; Gras LA; Prins JM
    AIDS Care; 2009 Jul; 21(7):842-50. PubMed ID: 20024740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV stigma and depressive symptoms are related to adherence and virological response to antiretroviral treatment among immigrant and indigenous HIV infected patients.
    Sumari-de Boer IM; Sprangers MA; Prins JM; Nieuwkerk PT
    AIDS Behav; 2012 Aug; 16(6):1681-9. PubMed ID: 22198315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with HIV-1 virological failure in an outpatient clinic for HIV-infected people in Haiphong, Vietnam.
    Huong DT; Bannister W; Phong PT; Kirk O; Peters L
    Int J STD AIDS; 2011 Nov; 22(11):659-64. PubMed ID: 22096052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial.
    Flandre P; Peytavin G; Meiffredy V; Saidi Y; Descamps D; Delagnes M; Brun-Vézinet F; Raffi F;
    Antivir Ther; 2002 Jun; 7(2):113-21. PubMed ID: 12212923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of different patterns of nonadherence on the outcome of highly active antiretroviral therapy in patients with long-term follow-up.
    Knobel H; Urbina O; González A; Sorlí ML; Montero M; Carmona A; Guelar A
    HIV Med; 2009 Jul; 10(6):364-9. PubMed ID: 19490179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy].
    Jambroes M; Weverling GJ; Reiss P; Danner SA; Jurriaans S; ten Veen JH; van der Ende ME; Schutten M; Schneider MM; Schuurman R; Mulder JW; Kroes AC; Lange JM; de Wolf F;
    Ned Tijdschr Geneeskd; 2001 Aug; 145(33):1591-7. PubMed ID: 11534377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
    Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
    Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applying the theory of planned behavior to explore HAART adherence among HIV-positive immigrant Latinos: elicitation interview results.
    Vissman AT; Hergenrather KC; Rojas G; Langdon SE; Wilkin AM; Rhodes SD
    Patient Educ Couns; 2011 Dec; 85(3):454-60. PubMed ID: 21208772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study.
    Weber R; Huber M; Rickenbach M; Furrer H; Elzi L; Hirschel B; Cavassini M; Bernasconi E; Schmid P; Ledergerber B;
    HIV Med; 2009 Aug; 10(7):407-16. PubMed ID: 19490174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence over 48 weeks in an antiretroviral clinical trial: variable within patients, affected by toxicities and independently predictive of virological response.
    Nieuwkerk P; Gisolf E; Sprangers M; Danner S;
    Antivir Ther; 2001 Jun; 6(2):97-103. PubMed ID: 11491422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy.
    Sungkanuparph S; Groger RK; Overton ET; Fraser VJ; Powderly WG
    HIV Med; 2006 Oct; 7(7):437-41. PubMed ID: 16925729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly active antiretroviral therapy adherence and its determinants in selected hospitals from south and central Ethiopia.
    Beyene KA; Gedif T; Gebre-Mariam T; Engidawork E
    Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1007-15. PubMed ID: 19650153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk Factors for Non-Adherence to cART in Immigrants with HIV Living in the Netherlands: Results from the ROtterdam ADherence (ROAD) Project.
    Been SK; van de Vijver DA; Nieuwkerk PT; Brito I; Stutterheim SE; Bos AE; Wolfers ME; Pogány K; Verbon A
    PLoS One; 2016; 11(10):e0162800. PubMed ID: 27706251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy.
    Moore DM; Hogg RS; Yip B; Wood E; Harris M; Montaner JS
    HIV Med; 2006 Jul; 7(5):311-6. PubMed ID: 16945076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time patterns of adherence and long-term virological response to non-nucleoside reverse transcriptase inhibitor regimens in the Stratall ANRS 12110/ESTHER trial in Cameroon.
    Meresse M; Carrieri MP; Laurent C; Kouanfack C; Protopopescu C; Blanche J; Cohen J; Laborde-Balen G; Aghokeng AF; Spire B; Moatti JP; Delaporte E; Boyer S;
    Antivir Ther; 2013; 18(1):29-37. PubMed ID: 23358393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients.
    Cicconi P; Cozzi-Lepri A; Castagna A; Trecarichi EM; Antinori A; Gatti F; Cassola G; Sighinolfi L; Castelli P; d'Arminio Monforte A;
    HIV Med; 2010 Feb; 11(2):104-13. PubMed ID: 19732176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Percentage of adherence correlates with the risk of protease inhibitor (PI) treatment failure in HIV-infected patients.
    Casado JL; Sabido R; Perez-Elías MJ; Antela A; Oliva J; Dronda F; Mejía B; Fortún J
    Antivir Ther; 1999; 4(3):157-61. PubMed ID: 12731755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
    Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G
    Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.